Procter & Gamble
http://www.pg.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Procter & Gamble
GSK Makes New Adult Immunization Push, Seeks Reimbursement Changes Following RSV Approvals
From ACIP to Part D to data transparency, GSK has several policy asks as it prepares to launch its new RSV vaccine for older adults. The Pink Sheet spoke with GSK’s vaccine policy lead about the firm’s new data platform and the worrisome US vaccination trends following the Covid pandemic.
India Clinical Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other
Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice